Stories

In the news

Press releases

Stories

Prime Insights

Media resources

Section divider

Stories 2020

March 19, 2020

Prime Highlights Innovative Strategies for Payers and Patients at PBMI National Conference

Prime showcases how leveraging data, technology and intelligence contains costs and improves the patient experience.


March 18, 2020

Risdiplam approaching mid-2020 PDUFA date 

This will be the third, high cost drug treatment option emerging for spinal muscular atrophy in less than five years; many more are in the pipeline. 


March 13, 2020

April 2020 decisions expected from the FDA

This synopsis looks ahead to the new drugs expecting an FDA decision in the month of April. 


February 14, 2020

March 2020 decisions expected from the FDA

This synopsis looks ahead to the new drugs expecting an FDA decision in the month of March. March 2020 decisions.


February 19, 2020

PrimeCares: Improving the health of our communities through good works

Prime’s employee volunteers and financial contributions make a difference.  


January 15, 2020

February 2020 decisions expected from the FDA

A synopsis of the new drugs expecting an FDA decision in the month of February.


January 20, 2020

Breakthrough therapy for cystic fibrosis

Trikafka’s triple combination therapy may cover 90% of patients with cystic fibrosis.


January 22, 2020

FDA issues its first approval for an oral CGRP formulation for acute migraine 

Ubrelvy™ brings a new treatment option (oral) to a new drug class (CGRP) for patients with migraine.  Prime stays on top of the drug pipeline so our clients don’t fall behind.